Today’s Research Reports on Valeant Pharmaceuticals, CRH Medical, Covalon Technologies and DiaMedica Therapeutics

NEW YORK, NY / ACCESSWIRE / April 10, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI has Initiated Coverage Today on:

Valeant Pharmaceuticals International, Inc.
https://rdinvesting.com/news/?ticker=VRX.TO

CRH Medical Corp.
https://rdinvesting.com/news/?ticker=CRH.TO

Covalon Technologies Ltd.
https://rdinvesting.com/news/?ticker=COV.V

DiaMedica Therapeutics Inc.
https://rdinvesting.com/news/?ticker=DMA.V

Valeant Pharmaceuticals stock moved 1.52% higher Monday, to close the day at $20.03. The stock recorded a trading volume of 1,111,832 shares, which was below its three months average volume of 1,581,818 shares. In the last year, Valeant Pharmaceuticals shares have traded in a range of 11.20 – 30.56. The share price has gained 78.84% from its 52 week low. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $20.97 is below its 200-day moving average of $21.55. Shares of Valeant Pharmaceuticals are trading at a Price to Earnings ratio of 2.93. Shares of Valeant Pharmaceuticals have fallen approximately 23.55 percent year-to-date.

Access RDI’s Valeant Pharmaceuticals International, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=VRX.TO

On Monday, shares of CRH Medical recorded a trading volume of 133,970 shares, which was below the three months average volume of 251,009 shares. The stock ended the day 1.73% higher at 3.53. The share price has gained 89.78% from its 52-week low with a 52-week trading range of 1.86 – 12.35. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $3.56 is greater than its 200-day moving average of $3.17. Shares of CRH Medical Corp. are trading at a Price to Earnings ratio of 40.57. Shares of CRH Medical have gained approximately 6.65 percent year-to-date.

Access RDI’s CRH Medical Corp. Research Report at:
https://rdinvesting.com/news/?ticker=CRH.TO

Covalon Technologies’ stock moved 5.66% lower Monday, to close the day at $4.00. The stock recorded a trading volume of 5,600 shares, which was below its three months average volume of 39,131 shares. In the last year, Covalon Technologies’ shares have traded in a range of 1.86 – 8.00. The share price has gained 115.05% from its 52 week low. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $4.89 is greater than its 200-day moving average of $4.76. Shares of the company are trading at a Price to Earnings ratio of 49.38. Shares of Covalon Technologies have fallen approximately 18.20 percent year-to-date.

Access RDI’s Covalon Technologies Ltd. Research Report at:
https://rdinvesting.com/news/?ticker=COV.V

On Monday, shares of DiaMedica Therapeutics recorded a trading volume of 1,089,467 shares, which was above the three months average volume of 209,163 shares. The stock ended the day 9.52% higher at 0.46. The share price has gained 119.05% from its 52-week low with a 52-week trading range of 0.21 – 0.48. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $0.39 is greater than its 200-day moving average of $0.36. Shares of DiaMedica Therapeutics have gained approximately 58.62 percent year-to-date.

Access RDI’s DiaMedica Therapeutics Inc. Research Report at:
https://rdinvesting.com/news/?ticker=DMA.V

Our Actionable Research on Valeant Pharmaceuticals International, Inc. (TSX:VRX.TO), CRH Medical Corp. (TSX:CRH.TO), Covalon Technologies Ltd. (TSXV:COV.V) and DiaMedica Therapeutics Inc. (TSXV:DMA.V) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute

SOURCE: RDInvesting.com

ReleaseID: 495639